HCA Healthcare (NYSE:HCA) PT Raised to $395.00 at Wells Fargo & Company

HCA Healthcare (NYSE:HCA) had its target price hoisted by investment analysts at Wells Fargo & Company from $365.00 to $395.00 in a report issued on Tuesday, Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s target price indicates a potential downside of 3.67% from the company’s current price.

Several other research firms have also commented on HCA. Cantor Fitzgerald restated an “overweight” rating and issued a $392.00 price objective on shares of HCA Healthcare in a research note on Tuesday, October 1st. Barclays lifted their price target on shares of HCA Healthcare from $376.00 to $396.00 and gave the company an “overweight” rating in a report on Wednesday, July 24th. Truist Financial increased their price target on HCA Healthcare from $390.00 to $430.00 and gave the stock a “buy” rating in a research note on Monday, August 19th. KeyCorp started coverage on HCA Healthcare in a research report on Friday, October 11th. They set an “overweight” rating and a $475.00 target price for the company. Finally, StockNews.com upgraded HCA Healthcare from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 1st. Five analysts have rated the stock with a hold rating, fourteen have issued a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $367.15.

HCA Healthcare Price Performance

NYSE HCA opened at $410.03 on Tuesday. The stock has a market capitalization of $107.39 billion, a price-to-earnings ratio of 20.44, a PEG ratio of 1.44 and a beta of 1.67. The company has a debt-to-equity ratio of 27.11, a current ratio of 1.06 and a quick ratio of 0.94. HCA Healthcare has a 1-year low of $215.96 and a 1-year high of $417.14. The business’s fifty day moving average price is $394.72 and its 200-day moving average price is $352.30.

HCA Healthcare (NYSE:HCA) last posted its quarterly earnings data on Tuesday, July 23rd. The company reported $5.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.97 by $0.53. The company had revenue of $17.49 billion for the quarter, compared to the consensus estimate of $17.05 billion. HCA Healthcare had a net margin of 8.40% and a return on equity of 553.13%. The firm’s revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm posted $4.29 earnings per share. On average, equities analysts predict that HCA Healthcare will post 22.51 earnings per share for the current year.

Insider Buying and Selling

In other HCA Healthcare news, EVP Michael S. Cuffe sold 8,358 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $385.42, for a total transaction of $3,221,340.36. Following the completion of the transaction, the executive vice president now owns 29,678 shares in the company, valued at $11,438,494.76. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other HCA Healthcare news, EVP Michael S. Cuffe sold 8,358 shares of the company’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $385.42, for a total value of $3,221,340.36. Following the transaction, the executive vice president now owns 29,678 shares of the company’s stock, valued at $11,438,494.76. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Kathleen M. Whalen sold 2,987 shares of the company’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $363.51, for a total transaction of $1,085,804.37. Following the completion of the transaction, the senior vice president now owns 9,454 shares in the company, valued at approximately $3,436,623.54. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 15,345 shares of company stock valued at $5,747,945. Company insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On HCA Healthcare

Several hedge funds have recently made changes to their positions in HCA. Bangor Savings Bank increased its holdings in HCA Healthcare by 112.5% during the second quarter. Bangor Savings Bank now owns 85 shares of the company’s stock valued at $27,000 after buying an additional 45 shares during the period. MFA Wealth Advisors LLC purchased a new stake in shares of HCA Healthcare during the 2nd quarter worth $27,000. Unique Wealth Strategies LLC bought a new position in HCA Healthcare in the second quarter worth about $28,000. GPS Wealth Strategies Group LLC grew its position in shares of HCA Healthcare by 284.0% in the 2nd quarter. GPS Wealth Strategies Group LLC now owns 96 shares of the company’s stock worth $31,000 after buying an additional 71 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. acquired a new stake in HCA Healthcare in the second quarter valued at approximately $33,000. 62.73% of the stock is currently owned by hedge funds and other institutional investors.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.